Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
NCT03935893
Recruiting
This is a Phase 2 study to evaluate the efficacy of a non-myeloablative lymphodepleting preparative regimen followed by infusion of autologous TIL and high-dose aldesleukin in patients with locally advanced, recurrent, or metastatic cancer associated with one of the following cancer types: 1.) gastric/esophagogastric, 2.) colorectal, 3.) pancreatic, 4.) sarcoma, 5.) mesothelioma, 6.) neuroendocrine, 7.) squamous cell cancer, 8.) Merkle cell, 9.) mismatch repair deficient and/or microsatellite un... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/07/2025
Locations: UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania
Conditions: Gastric Cancer, Colorectal Cancer, Pancreatic Cancer, Sarcoma, Mesothelioma, Neuroendocrine Tumors, Squamous Cell Cancer, Merkel Cell Carcinoma, Mismatch Repair Deficiency, Microsatellite Instability
Register for Updates
A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome
NCT05027945
Recruiting
Background: Allogeneic hematopoietic stem cell transplant involves taking blood stem cells from a donor and giving them to a recipient. The transplants are used to treat certain diseases and cancers. Researchers want to see if the transplant can treat VEXAS Syndrome. Objective: To see if stem cell transplants can be successfully performed in people with VEXAS and even improve the disease. Eligibility: People ages 18-75 who have VEXAS Syndrome that has caused significant health problems and... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/03/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Immunodeficiency, Hematopoietic Stem Cell Transplantation
Register for Updates
Haploidentical HCT for Severe Aplastic Anemia
NCT04558736
Recruiting
This study is a prospective, single center phase II clinical trial in which patients with Severe Aplastic Anemia (SAA) ) will receive a haploidentical transplantation. The purpose of this study is to learn more about newer methods of transplanting blood forming cells donated by a family member that is not fully matched to the patient. This includes studying the effects of the chemotherapy, radiation, the transplanted cell product and additional white blood cell (lymphocyte) infusions on the pati... Read More
Gender:
ALL
Ages:
21 years and below
Trial Updated:
07/03/2025
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Aplastic Anemia, Bone Marrow Failure Syndrome
Register for Updates
Intracerebroventricular Administration of CD19-CAR T Cells (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/Mem T-lymphocytes) for the Treatment of Central Nervous System Lymphoma
NCT05625594
Recruiting
This phase I trial tests the safety, side effects, and best dose of intracerebroventricularly (ICV) administered CD19-chimeric antigen receptor (CAR) T cells in treating patients with central nervous system (CNS) lymphoma. CAR T cell therapy is a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. T cells are taken from a patient's blood. Then the gene for a special receptor that binds to a certain protein,... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/02/2025
Locations: City of Hope Medical Center, Duarte, California
Conditions: Central Nervous System Lymphoma
Register for Updates
Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma
NCT00878254
Completed
The investigator(s) hypothesize that Rituximab together with combination chemotherapy, followed by Rituximab maintenance therapy, will provide better disease control with improved response rates and overall survival in patients with previously untreated Mantle Cell Lymphoma (MCL).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/02/2025
Locations: University of Miami, Miami, Florida
Conditions: Mantle-Cell Lymphoma
Register for Updates
Umbilical Cord Blood Transplantation From Unrelated Donors
NCT03016806
Recruiting
This study is a single-center, treatment protocol with 4 possible preparative regimens, designed to validate the process of umbilical cord blood stem cell transplantation at our institution.
Gender:
ALL
Ages:
Between 2 months and 75 years
Trial Updated:
07/02/2025
Locations: Wilmot Cancer Institute, Rochester, New York
Conditions: Acute Leukemia, Immune Deficiency Disorder, Congenital Hematological Disorder, Metabolism Disorder, Aplastic Anemia, Myelodysplastic Syndromes, Chronic Leukemia, Lymphoma, Multiple Myeloma, Solid Tumor
Register for Updates
A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer
NCT05989828
Recruiting
This phase Ib trial tests the safety, side effects and best dose of anti-HLA-A2/NY-ESO-1 T-cell receptor (TCR)-transduced autologous T lymphocytes (A2-ESO-1 TCR-T cells) in treating patients with NY-ESO-1 overexpression positive triple negative breast cancer (TNBC) that has come back after a period of improvement (relapsed/recurrent) or that does not respond to treatment (refractory), and that may have spread from where it first started (primary site) to nearby tissue, lymph nodes (advanced) or... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/01/2025
Locations: USC / Norris Comprehensive Cancer Center, Los Angeles, California
Conditions: Triple Negative Breast Cancer
Register for Updates
GFRα4 CAR T Cells in MTC Patients
NCT04877613
Active Not Recruiting
This is an open-label phase 1 study to assess the safety and feasibility of autologous T cells expressing a single-chain scFv targeting GFRα4 with tandem TCR/CD3ζ and 4-1BB (TCRζ/4-1BB) co-stimulatory domains (referred to as "CART-GFRa4 cells") in patients with incurable medullary thyroid cancer (MTC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/01/2025
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Metastatic Medullary Thyroid Cancer, Recurrent Thyroid Gland Medullary Carcinoma
Register for Updates
Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents
NCT03020030
Active Not Recruiting
Acute lymphoblastic leukemia (ALL) is the most common cancer diagnosed in children. The cancer comes from a cell in the blood called a lymphocyte. Normal lymphocytes are produced in the bone marrow (along with other blood cells) and help fight infections. In ALL, the cancerous lymphocytes are called lymphoblasts. They do not help fight infection and crowd out the normal blood cells in the bone marrow so that the body cannot make enough normal blood cells. ALL is always fatal if it is not treated... Read More
Gender:
ALL
Ages:
Between 1 year and 21 years
Trial Updated:
07/01/2025
Locations: Boston Children's Hospital, Boston, Massachusetts +8 locations
Conditions: Acute Lymphoblastic Leukemia, Pediatric
Register for Updates
CAR-T Cells for HIV Infection
NCT04648046
Recruiting
This is a limited-center, open-label dose escalating phase I/IIa study of autologous T cells expressing LVgp120duoCAR molecules in people with HIV infection. It will follow a 3+3 design. Dose escalation decisions will be made when a minimum of three participants have completed the safety-evaluation period (45 days) at a given dose level. Cohort 1 will undergo infusion of a single low-dose regimen of LVgp120duoCAR-T cells. Cohort 2 will undergo non-ablative conditioning with cyclophosphamide, fol... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/01/2025
Locations: University of California, Davis, Sacramento, California +1 locations
Conditions: HIV Infections
Register for Updates
Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma
NCT00602667
Active Not Recruiting
RATIONALE: In this study a combination of anti-cancer drugs (chemotherapy) is used to treat brain tumors in young children. Using chemotherapy gives the brain more time to develop before radiation is given. The chemotherapy in this study includes the drug methotrexate. This drug was an important part of the two clinical trials which resulted in the best survival results for children less than 3 years of age with medulloblastoma. Most patients treated on this trial will also receive radiation whi... Read More
Gender:
ALL
Ages:
5 years and below
Trial Updated:
06/30/2025
Locations: Lucile Packard Children's Hospital at Stanford University Medical Center, Palo Alto, California +5 locations
Conditions: Brain and Central Nervous System Tumors
Register for Updates
A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)
NCT04529772
Active Not Recruiting
Phase 3 randomized, double-blind, placebo-controlled, study assessing the efficacy and safety of acalabrutinib plus rituximab,cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) vs placebo plus R-CHOP in subjects ≤75 years of age with previously untreated non-germinal center diffuse large B-cell lymphoma.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/30/2025
Locations: Research Site, Tucson, Arizona +254 locations
Conditions: Diffuse Large B-Cell Lymphoma
Register for Updates